Pyrazolyl-substituted heteroaryls and their use as medicaments
AssigneeBoehrnger Ingelheim International GmbH
InventorsMatthias Hoffmann, Georg Dahmann, Christian Gnamm, Daniel Fandrick, John Scott, Clive McCarthy
Life of this patent
Estimating the term…
Abstract
The invention relates to new substituted heteroaryls of formula 1 or of formula 1′ wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
Claims31
A compound of formula 1 or 1′,
- wherein A is either N or CH,
- wherein Y is either —O— or CH2,
- wherein R3 is a substituent in ortho- or in meta-position of the pyrazolyl-ring of formula 1 and is selected from the group consisting of linear or branched —C1-6-alkyl, —C1-6-haloalkyl, —C3-6-cycloalkyl, —C1-4-alkylene-C3-6-cycloalkyl, a five- or six-membered monocyclic heterocycle with 1, 2 or three heteroatoms each independently selected from O, S or N, a nine- to 10-membered bicyclic heterocycle with 1, 2 or 3 heteroatoms each independently selected from O, S or N,
- wherein R3 is optionally substituted by one, two, three or four substituents each independently from each other selected from the group consisting of halogen (F), —C1-3-alkyl, oxo, —CN
- wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl,
- and the pharmaceutically acceptable salts of the aforementioned compounds.
Dependencies are inferred from the claim text.